hemostemix-logo-small.jpg
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
February 25, 2019 08:30 ET | Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
hemostemix-logo-small.jpg
Hemostemix Provides Highlights of 2018 Accomplishments
January 17, 2019 08:30 ET | Hemostemix Inc.
CALGARY, Alberta, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on...
hemostemix-logo-small.jpg
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
January 03, 2019 08:00 ET | Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
hemostemix-logo-small.jpg
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
November 09, 2018 08:30 ET | Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...
hemostemix-logo-small.jpg
Hemostemix Announces Important Manufacturing Process Refinements
November 08, 2018 08:30 ET | Hemostemix Inc.
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its...
BioAdaptives, Inc Names Dr. James Rouse as President
May 15, 2018 09:00 ET | BioAdaptives Inc.
LAS VEGAS, May 15, 2018 (GLOBE NEWSWIRE) -- BioAdaptives, Inc. (OTC PINK:BDPT) announced Dr. James Rouse has been appointed to the board of Directors and accepted the position of President. He will...
BioStem Technologies (OTC: BSEM) Regenerative Medicine Patient Story
BioStem Technologies Inc. Announces Intent to Acquire GIINT
February 26, 2018 20:27 ET | BioStem Technologies, Inc.
Pompano Beach, FL, Feb. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies...
Hamilton Thorne and BCSI to Launch Incubator Retrofit Service for the Fertility and Developmental Biology Markets
January 04, 2017 08:30 ET | Hamilton Thorne; BCSI
BEVERLY, MA and TORONTO, ON--(Marketwired - Jan 4, 2017) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services, and Blood Cell...
Hamilton Thorne to Present at the 2016 LD Micro Main Event
November 30, 2016 08:30 ET | Hamilton Thorne
BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 30, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted...
Hamilton Thorne Reports 18% Sales Increase for the Quarter Ended September 30, 2016
November 28, 2016 09:17 ET | Hamilton Thorne
BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 28, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted...